Free Speech December
This article was originally published in RPM Report
Executive Summary
Government and industry experts comment on drug shortages, tax reform, patent reform and other important public policy topics.
You may also be interested in...
US HHS Nominee Becerra Treading Carefully On ‘March In’ Rights
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.
US FDA’s Big Transition: Not The Commissioner – The Drug Center
It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.
A New Start: President Biden Visits Pfizer
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: